ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
A spirit of clinically relevant discovery and accessible, understandable knowledge dissemination is the profound legacy, responsibility, and obligation that Rich will leave at ASCO, and we will honor him by continuing this work at the level of rigor and quality he established.
ASCO's chief medical officer Dr. Richard L. Schilsky and I discuss the refinement of cancer surgery, the critical importance of federally funded research, and ASCO's research priorities for the oncology community.
As we begin our work in 2020, I am excited that we are building on the remarkable successes of 2019, and the years before, with growing collaboration and sharpening focus.
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded.
We’re making progress in better understanding, and communicating, the many issues surrounding adverse events, although not as fast as we’d like. In the long run, our patients will benefit from all of these initiatives.
Many of the successful, FDA-approved drugs commonly used in cancer care were developed at small biotech or pharma companies—so what role do the "big fish" play?
Support for federal research funding for cancer is not about politics. It's about people. There is no one in our society—liberal, conservative, libertarian, or just don’t care—who isn’t touched in some way by cancer.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Advertisement